VPHIF (Valeo Pharma) Retained Earnings: $-76.67 Mil (As of Jul. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VPHIF Valeo Pharma Inc VPHIF
12 GF Score
Price $0.00
View Full Analysis

What is Valeo Pharma Retained Earnings?

Valeo Pharma VPHIF -99.00% 12 Retained Earnings is $-76.67 Mil as of Jul. 2024. GuruFocus rates VPHIF with a GF Score™ of 12/100.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Valeo Pharma's retained earnings for the quarter that ended in Jul. 2024 was $-76.67 Mil.

Valeo Pharma's quarterly retained earnings declined from Jan. 2024 ($-66.41 Mil) to Apr. 2024 ($-70.90 Mil) and declined from Apr. 2024 ($-70.90 Mil) to Jul. 2024 ($-76.67 Mil).

Valeo Pharma's annual retained earnings declined from Oct. 2021 ($-23.09 Mil) to Oct. 2022 ($-39.78 Mil) and declined from Oct. 2022 ($-39.78 Mil) to Oct. 2023 ($-59.99 Mil).


Valeo Pharma  (OTCPK:VPHIF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Valeo Pharma Retained Earnings Historical Data

* Premium members only.

The historical data trend for Valeo Pharma's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Valeo Pharma Retained Earnings Chart

Valeo Pharma Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Retained Earnings
Get a 7-Day Free Trial -7.37 -10.95 -23.09 -39.78 -59.99

Valeo Pharma Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.27 -59.99 -66.41 -70.90 -76.67
VPHIF
12GF Score
Valeo Pharma Inc VPHIF
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valeo Pharma Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-76.67 Mil mean?
Valeo Pharma (VPHIF) has a Retained Earnings of $-76.67 Mil as of Jul. 2024. Retained earnings is the amount of net income not issued to shareholders. View historical data on Valeo Pharma and its competitors.
Is Valeo Pharma's Retained Earnings too high?
Valeo Pharma's current Retained Earnings is $-76.67 Mil. Overall, Valeo Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Valeo Pharma's Retained Earnings compare to ZTS?
Valeo Pharma's Retained Earnings of $-76.67 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Drug Manufacturers company?
A good Retained Earnings depends on the Drug Manufacturers industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Valeo Pharma and its competitors. Valeo Pharma's current Retained Earnings is $-76.67 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valeo Pharma stock overvalued right now?
Valeo Pharma (VPHIF) has a current Retained Earnings of $-76.67 Mil. The current Retained Earnings is $-76.67 Mil. Valeo Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Valeo Pharma (VPHIF), the current Retained Earnings is $-76.67 Mil as of Jul. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Valeo Pharma Business Description

Address 16667, Hymus Boulevard, Kirkland, QC, CAN, H9H 4R9
Valeo Pharma Inc is a Canadian specialty pharmaceutical company focused on acquiring either through acquisitions, in-licensing, or similar arrangements. The company operates in two divisions: Branded prescription products and hospital specialty products. Its product portfolio includes medicines for Respiratory/Allergy, Ophthalmology, Neurology, and Oncology.
12GF Score

Get the complete analysis for VPHIF

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price